Medication info
Rovelito Tablet 300/20 mg (Irbesartan, Atorvastatin)

Rovelito Tablet 300/20 mg (Irbesartan, Atorvastatin)

Prescription medicationTabletOral
Ingredient · strength
Atorvastatin Calcium Trihydrate›21.7mg / 1 tabletIrbesartan›300mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle, 30 tablets/box [10 tablets/PTPX3]
Approval status
Active

MFDS item code 201401985 · Approved 2014.04.24 · Insurance code 643506890

Summary

Main use
Treatment of hypertension (including diabetic nephropathy), improvement of dyslipidemia, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, irbesartan/atorvastatin. ○ Irbesartan This medicine may be taken with or without food. 1. Essential hypertension Adults: Administer irbesartan 150 mg orally once daily; if the effect is insufficient, the dose may be increased to 300 mg. In general, blood pressure control over 24 hours is better with 150 mg once daily than with 75 mg once daily, but 75 mg may be considered in special cases (e.g., at the start of treatment, in patients on hemodialysis, or in elderly patients aged 75 years or older). If blood pressure is not adequately controlled with monotherapy, another antihypertensive may be administered concomitantly. The effect is increased particularly when used with a low dose of a diuretic (e.g., hydrochlorothiazide). 2. Nephropathy in patients with type 2 diabetes and hypertension Adults: It is recommended to start oral treatment with 150 mg of this medicine once daily and increase the dose to 300 mg for maintenance. If necessary, another antihypertensive may be administered concomitantly to achieve the target blood pressure. - Elderly patients Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients aged 75 years or older. - Patients with renal impairment Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients on hemodialysis. - Patients with hepatic impairment Dose adjustment is generally not specifically required in patients with mild to moderate hepatic impairment, but it is recommended not to exceed 150 mg per day. There is no clinical experience in patients with severe hepatic impairment. ○ Atorvastatin calcium Patients receiving atorvastatin should follow a standard cholesterol-lowering diet before and during treatment. This medicine may be taken at any time of day, with or without food. 1. Hyperlipidemia The recommended initial dose is atorvastatin 10 mg once daily, but treatment may be started at 20 mg or 40 mg once daily in patients who require a greater reduction in LDL cholesterol (40 mg only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered at a dose of 10 ~ 80 mg once daily. The initial and maintenance doses of this medicine should be individualized according to the patient's characteristics, taking into account treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or dose titration, and the dose adjusted accordingly. The treatment goal is to lower LDL cholesterol; therefore, measurement of LDL cholesterol is recommended when starting treatment and evaluating the response. However, if LDL cholesterol levels are not available, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia This medicine is administered at a dose of 10 ~ 80 mg once daily, in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when such lipid-lowering treatments are not available. - Patients with renal impairment: Renal disease does not affect plasma concentrations of atorvastatin or its LDL-cholesterol-lowering effect; therefore, dose adjustment is not necessary. - Elderly patients: Efficacy and safety in patients aged 70 years or older are similar to those in the general adult patient population.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension (including diabetic nephropathy), improvement of dyslipidemia, and prevention of cardiovascular disease

  • Essential hypertension
  • hypertension
  • renal disease
  • myocardial infarction
  • stroke
  • vascular surgery
  • chronic stable angina
  • retinopathy
  • albuminuria
  • congestive heart failure
  • angina
  • hyperlipidemia
View approved original text

This medication combines two drugs, Irbesartan and Atorvastatin, to control blood pressure and reduce the risk of cardiovascular diseases. Irbesartan is primarily used in patients with essential hypertension and renal disease in patients with type 2 diabetes. Atorvastatin reduces the risk in patients with risk factors associated with coronary heart disease such as myocardial infarction, stroke, and angina, and decreases the risk of hospitalization due to congestive heart failure. It is also effective in treating hyperlipidemia and helps regulate cholesterol and triglyceride levels in the blood. Therefore, this medication is used to improve cardiovascular health by managing blood pressure and blood lipids.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, irbesartan/atorvastatin. ○ Irbesartan This medicine may be taken with or without food. 1. Essential hypertension Adults: Administer irbesartan 150 mg orally once daily; if the effect is insufficient, the dose may be increased to 300 mg. In general, blood pressure control over 24 hours is better with 150 mg once daily than with 75 mg once daily, but 75 mg may be considered in special cases (e.g., at the start of treatment, in patients on hemodialysis, or in elderly patients aged 75 years or older). If blood pressure is not adequately controlled with monotherapy, another antihypertensive may be administered concomitantly. The effect is increased particularly when used with a low dose of a diuretic (e.g., hydrochlorothiazide). 2. Nephropathy in patients with type 2 diabetes and hypertension Adults: It is recommended to start oral treatment with 150 mg of this medicine once daily and increase the dose to 300 mg for maintenance. If necessary, another antihypertensive may be administered concomitantly to achieve the target blood pressure. - Elderly patients Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients aged 75 years or older. - Patients with renal impairment Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients on hemodialysis. - Patients with hepatic impairment Dose adjustment is generally not specifically required in patients with mild to moderate hepatic impairment, but it is recommended not to exceed 150 mg per day. There is no clinical experience in patients with severe hepatic impairment. ○ Atorvastatin calcium Patients receiving atorvastatin should follow a standard cholesterol-lowering diet before and during treatment. This medicine may be taken at any time of day, with or without food. 1. Hyperlipidemia The recommended initial dose is atorvastatin 10 mg once daily, but treatment may be started at 20 mg or 40 mg once daily in patients who require a greater reduction in LDL cholesterol (40 mg only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered at a dose of 10 ~ 80 mg once daily. The initial and maintenance doses of this medicine should be individualized according to the patient's characteristics, taking into account treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or dose titration, and the dose adjusted accordingly. The treatment goal is to lower LDL cholesterol; therefore, measurement of LDL cholesterol is recommended when starting treatment and evaluating the response. However, if LDL cholesterol levels are not available, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia This medicine is administered at a dose of 10 ~ 80 mg once daily, in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when such lipid-lowering treatments are not available. - Patients with renal impairment: Renal disease does not affect plasma concentrations of atorvastatin or its LDL-cholesterol-lowering effect; therefore, dose adjustment is not necessary. - Elderly patients: Efficacy and safety in patients aged 70 years or older are similar to those in the general adult patient population.

Precautions

This medication should not be used during pregnancy. If pregnancy is confirmed, the medication should be stopped immediately as it can cause serious harm to the fetus and newborn. It should not be used in patients with impaired liver function or active liver disease, and if signs of liver dysfunction appear, the doctor should be informed immediately. If there are symptoms of myalgia, muscle weakness, or severe myopathy, the patient should stop taking it immediately and seek medical attention. Careful monitoring is important as muscle enzyme levels may become abnormally elevated. As blood pressure may drop too low or symptoms like dizziness and fainting may occur, elderly patients or those struggling to control their blood pressure should start at a low dose and be closely monitored. There is a risk for elevated blood potassium levels, so patients at risk of hyperkalemia should have regular blood tests. When taking with other antihypertensives, diuretics, or potassium supplements, there may be drug interactions, so consult with a doctor or pharmacist. Rarely, allergic reactions, angioedema, or severe skin rashes can occur, so if any of these symptoms arise, the medication should be stopped immediately and medical personnel should be notified. The safety and efficacy of this medication have not been established in children, and it should not be used in patients under 18 years of age. Breastfeeding women are advised not to take this medication; if necessary, breastfeeding should be discontinued. In the case of overdose, symptoms such as hypotension or heart rhythm abnormalities may occur, so immediate medical assistance should be sought, as there are no specific antidotes, and treatment based on symptoms is necessary. While taking this medication, caution is advised when driving or operating machinery, as dizziness or fatigue may occur.

Side effects

  • Palpitations
  • chest discomfort
  • headache
  • elevated blood triglycerides
  • diarrhea
  • dyspepsia
  • vomiting
  • gastrointestinal disorders
  • gastritis
  • toothache
Show 203 more
  • dizziness
  • lumbar pain
  • myalgia
  • dyspnea
  • epistaxis
  • rhinorrhea
  • visual disturbances
  • macular degeneration
  • chest pain
  • fatigue
  • edema
  • weakness
  • nasopharyngitis
  • upper respiratory infection
  • sprain
  • hyponatremia
  • elevated serum creatine phosphokinase
  • hematuria
  • elevated γ-GTP
  • exacerbation of angina
  • myocardial infarction
  • malignant liver neoplasm
  • gastric cancer
  • limb weakness
  • pyelonephritis
  • hypovolemic shock
  • rheumatoid arthritis
  • increased blood pressure
  • hypotension
  • localized numbness
  • exacerbation of dizziness
  • epilepsy
  • exacerbation of headache
  • skin laceration
  • abdominal pain
  • hemorrhoids
  • transient blackouts
  • thrombocytopenia
  • allergic reaction
  • hepatitis
  • liver function abnormalities
  • renal failure
  • anemia
  • hypoglycemia
  • angioedema
  • hyperkalemia
  • shock
  • syncope
  • loss of consciousness
  • renal failure
  • jaundice
  • rhabdomyolysis
  • constipation
  • malaise
  • chest pain
  • peripheral edema
  • fever
  • rhinosinusitis
  • hyperglycemia
  • hypoglycemia
  • weight gain
  • loss of appetite
  • abdominal distension
  • pharyngeal and laryngeal pain
  • nosebleed
  • insomnia
  • nightmares
  • sensory abnormalities
  • sensory reduction
  • taste abnormalities
  • amnesia
  • peripheral neuropathy
  • arthralgia
  • limb pain
  • muscle cramps
  • joint swelling
  • back pain
  • neck pain
  • muscle fatigue
  • myopathy
  • myositis
  • tendon disorders
  • muscle rupture
  • lupus-like syndrome
  • thrombocytopenia
  • anaphylaxis
  • cholestasis
  • liver failure
  • blurred vision
  • visual impairment
  • tinnitus
  • hearing loss
  • urticaria
  • skin rash
  • hair loss
  • angioneurotic edema
  • erythema multiforme
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • gynecomastia
  • abnormal liver function tests
  • increased serum creatinine kinase
  • positive urinary leukocytes
  • nightmares
  • vomiting
  • abdominal abnormalities
  • cholestasis
  • cholestatic jaundice
  • dry mouth
  • rectal bleeding
  • esophagitis
  • stomatitis
  • gallbladder pain
  • cheilitis
  • gastric and duodenal ulcer
  • dysphagia
  • melena
  • gingival bleeding
  • postprandial nausea
  • bronchitis
  • pneumonia
  • asthma
  • sensory abnormalities
  • drowsiness
  • forgetfulness
  • abnormal dreams
  • decreased libido
  • emotional instability
  • coordination ataxia
  • torticollis
  • facial paralysis
  • hyperkinesia
  • depression
  • hypertonia
  • muscle cramps
  • muscle fatigue
  • myositis
  • muscle diseases
  • synovial cyst
  • tenosynovitis
  • myasthenia gravis
  • pain in the neck
  • contracture
  • elevated CK
  • increased serum myoglobin
  • pruritus
  • dry skin
  • sweating
  • acne
  • eczema
  • skin ulcer
  • erectile dysfunction
  • urinary tract infection
  • frequent urination
  • cystitis
  • hematuria
  • difficult urination
  • kidney stones
  • nocturia
  • epididymitis
  • breast fibrocystic changes
  • vaginal bleeding
  • albuminuria
  • breast enlargement
  • cervical discharge
  • nephritis
  • urinary incontinence
  • urinary retention
  • urgency
  • abnormal ejaculation
  • uterine bleeding
  • discolored urine
  • hypoglycemia
  • hyperglycemia
  • increased appetite
  • vasomotor edema
  • angina
  • facial edema
  • fever
  • cervical stiffness
  • generalized edema
  • amblyopia
  • dry eyes
  • refractive errors
  • ocular hemorrhage
  • hearing loss
  • glaucoma
  • perception changes
  • taste loss
  • taste distortion
  • leukopenia
  • decreased testosterone
  • increased cholinesterase
  • elevated TSH
  • elevated ACTH
  • decreased aldosterone
  • cerebral infarction
  • tachycardia
  • skin and mucous membrane syndrome
  • toxic epidermal necrolysis
  • erythema multiforme
  • immune-mediated necrotizing myopathy
  • severe muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and at a safe temperature between 1 degree and 30 degrees Celsius. Therefore, it is advisable to avoid direct sunlight and not place it in excessively hot or cold locations.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle, 30 tablets/box [10 tablets/PTPX3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.